Allogene Therapeutics (ALLO) Receivables - Other: 2020-2025
Historic Receivables - Other for Allogene Therapeutics (ALLO) over the last 4 years, with Sep 2025 value amounting to $23.5 million.
- Allogene Therapeutics' Receivables - Other rose 5.16% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 5.16%. This contributed to the annual value of $20.8 million for FY2024, which is N/A change from last year.
- As of Q3 2025, Allogene Therapeutics' Receivables - Other stood at $23.5 million, which was down 0.05% from $23.5 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Receivables - Other registered a high of $23.5 million during Q2 2025, and its lowest value of $1.2 million during Q1 2023.
- Moreover, its 3-year median value for Receivables - Other was $21.6 million (2025), whereas its average is $19.2 million.
- Per our database at Business Quant, Allogene Therapeutics' Receivables - Other surged by 142.86% in 2022 and then crashed by 87.23% in 2023.
- Allogene Therapeutics' Receivables - Other (Quarterly) stood at $4.1 million in 2021, then tumbled by 63.41% to $1.5 million in 2022, then plummeted by 87.23% to $1.2 million in 2023, then reached $20.8 million in 2024, then rose by 5.16% to $23.5 million in 2025.
- Its Receivables - Other stands at $23.5 million for Q3 2025, versus $23.5 million for Q2 2025 and $21.6 million for Q1 2025.